# Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

> **NCT00493805** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 59 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Insulin Resistance

## Interventions

- **DRUG:** Combination of pegylated interferon alfa-2b and ribavirin
- **DRUG:** Combination of pegylated interferon alfa-2b and ribavirin

## Key facts

- **NCT ID:** NCT00493805
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Slow Enrollment
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493805, "Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00493805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*